Damora Therapeutics (DMRA) earnings history
Most recent quarter
- Fiscal period
- Q2 2025
- Period end
- Jun 30, 2025
- EPS actual
- −$2.60
- EPS estimate
- $0.00
- EPS surprise
- +0.00%
- Revenue surprise
- +0.00%
- Revenue
- $0.00
- Revenue estimate
- $0.00
- Reported
- Aug 5, 2025
Damora Therapeutics' most recent quarter in the table is Q2 2025, reported August 5, 2025. It posted a loss of $2.60 per share. No estimate was given for the quarter, so there is no surprise to measure, and the table shows no revenue for any period. A year earlier, Q2 2024 showed a loss of $4.92 per share, so the loss narrowed by about 47%.
Every quarter in the table, back to Q3 2020, was a loss, but per-share losses have shrunk. The annual loss was $51.25 per share in 2021, $60.75 in 2022 and $36.47 in 2023. The quarters shown since then were smaller, ranging from $5.05 in Q1 2024 down to $1.92 in Q1 2025, the narrowest loss in the table. The record has a gap: there is no Q4 2024 row, so 2024 cannot be totalled. Where estimates were given, the loss came in narrower than expected in 15 of 17 quarters.
Damora reported Q3 between November 1 and November 8 in each year from 2021 to 2024. The table shows no report after August 2025, so the next update here will add the later quarters.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2025 | Aug 5, 2025 | $0.00 | −$2.60 | +0.00% | $0.00 | SEC |
| Q1 2025 | May 8, 2025 | $0.00 | −$1.92 | +0.00% | $0.00 | SEC |
| Q3 2024 | Nov 1, 2024 | −$3.70 | −$3.39 | +8.38% | $0.00 | SEC |
| Q2 2024 | Aug 12, 2024 | −$6.04 | −$4.92 | +18.48% | $0.00 | SEC |
| Q1 2024 | Apr 29, 2024 | −$10.25 | −$5.05 | +50.73% | $0.00 | SEC |
| Q4 2023 | Mar 8, 2024 | −$8.75 | −$5.97 | +31.83% | $0.00 | SEC |
| Q3 2023 | Nov 6, 2023 | −$8.50 | −$7.50 | +11.76% | $0.00 | SEC |
| Q2 2023 | Jul 31, 2023 | −$14.67 | −$10.25 | +30.11% | $0.00 | SEC |
| Q1 2023 | Apr 28, 2023 | −$15.63 | −$12.75 | +18.40% | $0.00 | SEC |
| Q4 2022 | Mar 9, 2023 | −$14.25 | −$13.75 | +3.51% | $0.00 | SEC |
| Q3 2022 | Nov 8, 2022 | −$17.00 | −$13.50 | +20.59% | $0.00 | — |
| Q2 2022 | Jul 29, 2022 | −$17.25 | −$16.75 | +2.90% | $0.00 | — |
| Q1 2022 | Apr 29, 2022 | −$15.25 | −$16.75 | −9.84% | $0.00 | — |
| Q4 2021 | Feb 17, 2022 | −$14.00 | −$13.25 | +5.36% | $0.00 | — |
| Q3 2021 | Nov 4, 2021 | −$14.00 | −$12.50 | +10.71% | $0.00 | — |
| Q2 2021 | Aug 5, 2021 | −$13.50 | −$12.25 | +9.26% | $0.00 | — |
| Q1 2021 | May 4, 2021 | −$11.50 | −$13.25 | −15.22% | $0.00 | — |
| Q4 2020 | Mar 29, 2021 | −$22.95 | −$11.75 | +48.79% | $0.00 | — |
| Q3 2020 | Dec 11, 2020 | −$340.06 | −$19.00 | +94.41% | $0.00 | — |
Quarterly revenue
Frequently asked questions
When did Damora Therapeutics (DMRA) last report earnings?
Damora Therapeutics last reported on Aug 5, 2025, covering fiscal Q2 2025.
Did DMRA beat earnings estimates?
Damora Therapeutics reported EPS of −$2.60 for Q2 2025, in line with the $0.00 consensus estimate.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.